Loading…
Legend Biotech Corporation is projected to rise to $22.75 by 2027, a +19% move from its current price of $19.05. LEGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $18.38 | $19.07 | $19.78 | +0.09% |
| Aug 2 | $18.12 | $19.08 | $20.10 | +0.17% |
| Aug 3 | $17.93 | $19.10 | $20.35 | +0.26% |
| Aug 4 | $17.77 | $19.12 | $20.57 | +0.35% |
| Aug 5 | $17.63 | $19.13 | $20.77 | +0.44% |
| Aug 6 | $17.51 | $19.15 | $20.95 | +0.52% |
| Aug 7 | $17.40 | $19.17 | $21.12 | +0.61% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $17.40 | $19.17 | $21.12 | +0.61% |
| Week 2 | $16.81 | $19.28 | $22.12 | +1.23% |
| Week 3 | $16.40 | $19.40 | $22.95 | +1.85% |
| Week 4 | $16.08 | $19.52 | $23.70 | +2.47% |
| Week 5 | $15.81 | $19.64 | $24.40 | +3.10% |
| Week 6 | $15.58 | $19.76 | $25.06 | +3.73% |
| Week 7 | $15.38 | $19.88 | $25.70 | +4.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Legend Biotech Corporation is a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is cilta-cel, a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma. The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, and it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting BCMA for MM, which are in investigator-initiated Phase 1 clinical trials in China.
Legend Biotech has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
This description reflects the company’s role in developing cellular therapies and its key partnerships and headquarters as provided in the verified facts.
Legend Biotech Corporation (LEGN) is listed in the Healthcare sector and is currently priced at $19.27 with a market capitalization of $3.73B. The stock holds a rank of 1511 by market size in the available data.
The current price and the forecast picture together imply a measured near-term stance, with longer-term forecasts showing significant upside potential in select years. The outlook includes a neutral near term and increasingly bullish longer horizons according to the provided yearly figures.
Across the multi-year view, the forecast spans a wide range around the current price, with the 2026 average at $19.27 and a path toward higher averages and large upside by 2032–2050. The implied returns grow from flat in 2026 to double- and triple-digit ROI by 2032 and beyond, depending on the year.
Overall, the asset sits at a price close to its near-term support level while the longer-range forecast indicates a bullish trajectory with substantial upside potential in the 2030–2050 timeframe.
A major floor 52.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.0% away) — a key level to hold.
The nearest ceiling, 76.0% above — a clean break opens room to run.
A major ceiling 102.0% above — clearing it would confirm fresh momentum.
Key LEGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LEGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.69 | Sell | $19.83 | Sell |
| MA 10 | $21.45 | Sell | $21.22 | Sell |
| MA 20 | $23.98 | Sell | $23.38 | Sell |
| MA 50 | $28.11 | Sell | $25.66 | Sell |
| MA 100 | $24.91 | Sell | $25.59 | Sell |
| MA 200 | $24.61 | Sell | $26.46 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 24.78 | Buy |
| Stoch RSI (14) | 10.06 | Buy |
| CCI (20) | -119.43 | Sell |
| Williams %R (14) | -97.10 | Info |
| MACD (12,26,9) | -0.48 | Sell |
| ROC (12) | -25.79 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 2.90 | Buy |
| TRIX (15) | -1.12 | Sell |
| Awesome (5,34) | -7.24 | Sell |
| Ultimate (7,14,28) | 10.02 | Buy |
| Momentum (10) | -3.66 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 17.87 | Buy |
| ADX (14) | 31.98 | Sell |
| ATR (14) | 0.81 | Info |
The 30-day technical picture reflects a neutral stance, supported by a low RSI14 of 20, which sits in oversold territory, and two simple moving averages: SMA50 at $28.77 and SMA200 at $24.85.
The stock trades with a clear support level at $19.27 and a resistance at $36.28, with a 30-day price range between $14.84 and $25.01. This implies limited upside momentum in the near term given the current price sits near support and below the major moving averages.
Annualized volatility is high at 80%, underscoring the potential for significant price swings in the near term despite the neutral sentiment. Investors should consider the wide 30-day range and RSI context when assessing timing and risk.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.65 | $19.05 | $26.86 | 0% | Neutral | |
| $17.58 | $22.75 | $31.46 | +19% | Neutral | |
| $16.39 | $22.07 | $32.02 | +16% | Neutral | |
| $16.24 | $22.59 | $34.01 | +19% | Neutral | |
| $16.70 | $23.93 | $37.15 | +26% | Bullish | |
| $15.94 | $23.44 | $37.39 | +23% | Bullish | |
| $20.21 | $30.48 | $49.79 | +60% | Bullish | |
| $22.79 | $35.21 | $58.76 | +85% | Bullish | |
| $20.55 | $32.48 | $55.28 | +71% | Bullish | |
| $21.04 | $33.98 | $58.90 | +78% | Bullish | |
| $26.80 | $47.89 | $89.53 | +151% | Bullish | |
| $37.12 | $79.63 | $165.87 | +318% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.65 | $19.05 | $22.26 | +0.00% |
| August 2026 | $16.69 | $19.73 | $23.97 | +3.57% |
| September 2026 | $17.25 | $20.62 | $25.51 | +4.54% |
| October 2026 | $16.92 | $20.42 | $25.61 | -0.99% |
| November 2026 | $16.66 | $20.25 | $25.68 | -0.85% |
| December 2026 | $17.13 | $20.97 | $26.86 | +3.55% |
Click any year to see its month-by-month LEGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, LEGN could reach as high as $26.86, with a base case around $19.05 and support toward $16.65 — roughly 0% from $19.05. A consolidation phase looks the most probable path here.
Expect LEGN to range from $17.58 to $31.46 through 2027. The $22.75 average target implies a +19% move from current prices. That is up +19% on the projected 2026 average. Price action looks broadly range-bound.
The LEGN price prediction for 2028 points to an average of $22.07 (low $16.39, high $32.02) — a potential gain of +16% on today's $19.05. A consolidation phase looks the most probable path here.
In 2029, LEGN is projected to trade between $16.24 and $34.01, averaging $22.59 — a potential gain of +19% from today's $19.05. That is up +2% on the projected 2028 average. Price action looks broadly range-bound.
Legend Biotech Corporation's 2030 outlook centres on $23.93, within a $16.70 to $37.15 range. That is up +6% on the projected 2029 average. That marks a +26% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, LEGN could reach as high as $37.39, with a base case around $23.44 and support toward $15.94 — roughly +23% from $19.05. Momentum favours further upside here.
Expect LEGN to range from $20.21 to $49.79 through 2032. The $30.48 average target implies a +60% move from current prices. That is up +30% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The LEGN price prediction for 2033 points to an average of $35.21 (low $22.79, high $58.76) — a potential gain of +85% on today's $19.05. Momentum favours further upside here.
In 2034, LEGN is projected to trade between $20.55 and $55.28, averaging $32.48 — a potential gain of +71% from today's $19.05. That is -8% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
Legend Biotech Corporation's 2035 outlook centres on $33.98, within a $21.04 to $58.90 range. That is up +5% on the projected 2034 average. That marks a +78% change versus current levels. Momentum favours further upside here.
By 2040, LEGN could reach as high as $89.53, with a base case around $47.89 and support toward $26.80 — roughly +151% from $19.05. Buyers look set to stay in control over this stretch.
Expect LEGN to range from $37.12 to $165.87 through 2050. The $79.63 average target implies a +318% move from current prices. That is up +66% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in LEGN today (≈ 52.493438 LEGN) could be worth
$4,179.97
+$3,179.97 (+318%) by 2050 · US Dollar
Based on the average projected LEGN price of $79.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LEGNwould be worth at today's price.
$1,000 invested in LEGN on Jul 30, 2025 (≈ 24.74635 LEGN) would be worth
$471.42
-$528.58 (-52.9%) today · 0.47× · US Dollar
Based on a LEGN entry price of $40.41 vs. today's $19.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23.53 | $809.6 | -19.0% |
| 1 month ago | $28.88 | $659.63 | -34.0% |
| 3 months ago | $23.59 | $807.55 | -19.2% |
| 6 months ago | $17.5 | $1,088.57 | +8.9% |
| 1 year ago | $40.41 | $471.42 | -52.9% |
| All time (5.0y) ago | $43.08 | $442.2 | -55.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LEGN forecast.
Our base-case forecast reaches $38.00 around 2040.
Implied market cap at $38.00: $7.35B
Looking further out, the multi-year forecast shows a path from a 2026 average price of $19.27 to progressively higher levels, with bullish momentum developing from 2030 onward. The 2030 forecast has an average of $23.85 and a max of $37.78, with a 23.8% ROI and bullish sentiment, followed by continued bullish projections through 2031–2050. Notable yearly figures include 2032 average of $30.88 (60.2% ROI), 2033 average $35.65 (85% ROI), 2034 average $32.60 (69.2% ROI), 2035 average $34.10 (77% ROI), 2040 average $48.10 (149.6% ROI), and 2050 average $79.25 (311.3% ROI).
The forecast consistently marks sentiment as BULLISH from 2030 onward, reflecting an expectation of sustained upward movement despite the inherent uncertainty and risk in equity-like price forecasts. These are estimates, not guarantees, and actual results may differ due to market conditions and company-specific developments.
Tap a question to reveal the answer.
The 2030 forecast shows an average of $23.85 with a min of $16.32 and a max of $37.78, a ROI of 23.8%, and a BULLISH sentiment.
Forecasts indicate rising averages from 2026 onward with a shift to BULLISH sentiment from 2030, including a 2030 average of $23.85 and a 2050 average of $79.25 with a 311.3% ROI. The 2026 forecast is neutral with an average of $19.27 and a range to $27.64.
Yes. The 2032 max is $51.61 and the 2033 max is $60.95, indicating potential to surpass $50 in the forecast window.
The 2027 forecast lists a min of $17.61, an average of $23.04, a max of $32.28, a ROI of 19.6%, and a NEUTRAL sentiment.
For 2040, the average is $48.10 with a max of $92.66 and a ROI of 149.6% (bullish). For 2050, the average is $79.25 with a max of $170.94 and a ROI of 311.3% (bullish).
Legend Biotech Corporation Community Discussion
0Share your Legend Biotech Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.